INO Inovio Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INO

Price (delayed)

$11.31

Market cap

$293.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.48

Enterprise value

$286.87M

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO ...

Highlights
Inovio Pharmaceuticals's debt has shrunk by 57% YoY and by 56% QoQ
INO's EPS has surged by 53% year-on-year and by 10% since the previous quarter
INO's revenue has dropped by 93% year-on-year and by 14% since the previous quarter
The gross profit has dropped by 93% year-on-year and by 14% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inovio.com
Peers: PFE JNJ ARWR NVS

Key stats

What are the main financial stats of INO
Market
Shares outstanding
25.91M
Market cap
$293.05M
Enterprise value
$286.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.8
Price to sales (P/S)
367.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
400.07
Earnings
Revenue
$717,068
EBIT
-$123.85M
EBITDA
-$120.74M
Free cash flow
-$116.37M
Per share
EPS
-$5.48
Free cash flow per share
-$5
Book value per share
$4.04
Revenue per share
$0.03
TBVPS
$5.54
Balance sheet
Total assets
$129.11M
Total liabilities
$34.67M
Debt
$13.43M
Equity
$94.44M
Working capital
$88.28M
Liquidity
Debt to equity
0.14
Current ratio
4.77
Quick ratio
4.62
Net debt/EBITDA
0.05
Margins
EBITDA margin
-16,838%
Gross margin
100%
Net margin
-17,423.4%
Operating margin
-18,334.8%
Efficiency
Return on assets
-68.8%
Return on equity
-96.2%
Return on invested capital
-89.6%
Return on capital employed
-117.2%
Return on sales
-17,271.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INO stock price

How has the Inovio Pharmaceuticals stock price performed over time
Intraday
3.29%
1 week
12.31%
1 month
44.81%
1 year
82.94%
YTD
84.8%
QTD
39.98%

Financial performance

How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$717,068
Gross profit
$717,068
Operating income
-$131.47M
Net income
-$124.94M
Gross margin
100%
Net margin
-17,423.4%
INO's revenue has dropped by 93% year-on-year and by 14% since the previous quarter
The gross profit has dropped by 93% year-on-year and by 14% since the previous quarter
INO's net income is up by 48% year-on-year and by 8% since the previous quarter
INO's operating income is up by 45% YoY and by 9% QoQ

Growth

What is Inovio Pharmaceuticals's growth rate over time

Valuation

What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.8
P/S
367.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
400.07
INO's EPS has surged by 53% year-on-year and by 10% since the previous quarter
The stock's price to book (P/B) is 81% more than its last 4 quarters average of 1.5 but 69% less than its 5-year quarterly average of 8.8
The equity has plunged by 53% YoY and by 20% from the previous quarter
INO's revenue has dropped by 93% year-on-year and by 14% since the previous quarter
The P/S is 90% higher than the last 4 quarters average of 187.1 and 12% higher than the 5-year quarterly average of 317.4

Efficiency

How efficient is Inovio Pharmaceuticals business performance
INO's ROE is down by 11% from the previous quarter
INO's return on assets is down by 10% since the previous quarter and by 4.6% year-on-year
The company's return on invested capital fell by 10% QoQ but it rose by 4.1% YoY
INO's return on sales is down by 7% since the previous quarter

Dividends

What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INO.

Financial health

How did Inovio Pharmaceuticals financials performed over time
The total assets has dropped by 52% year-on-year and by 24% since the previous quarter
The company's total liabilities fell by 49% YoY and by 35% QoQ
Inovio Pharmaceuticals's debt is 86% lower than its equity
Inovio Pharmaceuticals's debt has shrunk by 57% YoY and by 56% QoQ
The equity has plunged by 53% YoY and by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.